Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 21:3:45.
doi: 10.3389/fcimb.2013.00045. eCollection 2013.

PGE(2) suppression of innate immunity during mucosal bacterial infection

Affiliations
Review

PGE(2) suppression of innate immunity during mucosal bacterial infection

Mallory Agard et al. Front Cell Infect Microbiol. .

Abstract

Prostaglandin E2 (PGE2) is an important lipid mediator in inflammatory and immune responses during acute and chronic infections. Upon stimulation by various proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulated by the expression of cyclooxygenases. Biologically active PGE2 is then able to signal through four primary receptors to elicit a response. PGE2 is a critical molecule that regulates the activation, maturation, migration, and cytokine secretion of several immune cells, particularly those involved in innate immunity such as macrophages, neutrophils, natural killer cells, and dendritic cells. Both Gram-negative and Gram-positive bacteria can induce PGE2 synthesis to regulate immune responses during bacterial pathogenesis. This review will focus on PGE2 in innate immunity and how bacterial pathogens influence PGE2 production during enteric and pulmonary infections. The conserved ability of many bacterial pathogens to promote PGE2 responses during infection suggests a common signaling mechanism to deter protective pro-inflammatory immune responses. Inhibition of PGE2 production and signaling during infection may represent a therapeutic alternative to treat bacterial infections. Further study of the immunosuppressive effects of PGE2 on innate immunity will lead to a better understanding of potential therapeutic targets within the PGE2 pathway.

Keywords: COX; bacteria; immunotherapeutic; infection; mucosal; prostaglandin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Modulation of PGE2 by pathogenic bacteria. PGE2 synthesis is initiated by the release of AA from the lipid cell membrane by the enzyme cPLA2. Either COX-1 (constitutively expressed) or COX-2 (inducible) can utilize AA as a substrate to produce the precursor PGH2. PGH2 is converted to biologically active PGE2 by means of the enzyme PGE2 synthase. PGE2 can then readily signal through one of four EP, denoted EP1, EP2, EP3, and EP4. Various pathogens influence PGE2 production and signaling along different steps of this pathway. Green arrows indicate activation of COX-2 or PGES, while red lines indicate inhibition of COX-2 or PGES by select pathogens. Blue lines indicate a potential role for EP signaling in pathogen survival.

References

    1. A S. K., Bansal K., Holla S., Verma-Kumar S., Sharma P., Balaji K. N. (2012). ESAT-6 induced COX-2 expression involves coordinated interplay between PI3K and MAPK signaling. Mol. Immunol. 49, 655–663 10.1016/j.molimm.2011.11.011 - DOI - PubMed
    1. Alba-Loureiro T. C., Martins E. F., Miyasaka C. K., Lopes L. R., Landgraf R. G., Jancar S., et al. (2004). Evidence that arachidonic acid derived from neutrophils and prostaglandin E2 are associated with the induction of acute lung inflammation by lipopolysaccharide of Escherichia coli. Inflamm. Res. 53, 658–663 10.1007/s00011-004-1308-7 - DOI - PubMed
    1. Aronoff D. M. (2012). Cyclooxygenase inhibition in sepsis: is there life after death? Mediat. Inflamm. 2012:696897 10.1155/2012/696897 - DOI - PMC - PubMed
    1. Aronoff D. M., Bergin I. L., Lewis C., Goel D., O'Brien E., Peters-Golden M., et al. (2012). E-prostanoid 2 receptor signaling suppresses lung innate immunity against Streptococcus pneumoniae. Prostaglandins Other Lipid Mediat. 98, 23–30 10.1016/j.prostaglandins.2012.03.002 - DOI - PMC - PubMed
    1. Aronoff D. M., Canetti C., Peters-Golden M. (2004). Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173, 559–565 - PubMed

MeSH terms